医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Open Monoclonal Technology Announces OmniAb Alliance With Amgen

2015年06月15日 AM06:12
このエントリーをはてなブックマークに追加


 

PALO ALTO, Calif.

Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Amgen Inc. with access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic™ human antibody generation platforms, jointly known as OmniAb. Amgen becomes OMT’s 12th non-academic partner globally with such multi-platform access.

Dr. Roland Buelow, OMT founder and CEO, said, “Amgen was an early protein therapeutics leader and became one of a few companies with transgenic mouse platforms for human antibody discovery in 2005 when they acquired Abgenix and its XenoMouse®. With the license from OMT, Amgen further builds on this capability as it gains access to complementary platforms for development of fully human, mono- and bispecific antibodies without any target restrictions.”

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the generation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with four transgenic animal platforms, jointly known as OmniAb.

OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. UniRat is the first transgenic rat generating fully human heavy chain-only antibodies and nanobodies for polyspecific applications.

All four OmniAb™ platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications.

Current partners include Amgen, Caltech, Celgene, Chugai, Genmab, Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, University of Nottingham and several undisclosed biotech and pharmaceutical companies. Animal hosting and OmniAb antibody discovery services are available via Antibody Solutions, Panoply Bio and Sage Labs in the US, Aldevron and Taconic Biosciences in Europe, and WuXi AppTec in China. For more information, please visit www.omtinc.net.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150614005086/en/

CONTACT

Open Monoclonal Technology, Inc.
Brian Lundstrom, +1-775-420-7750
bl@omtinc.net

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
  • Herbalife Nutrition Hong Kong and Po Leung Kuk Set New World Record in Launching Healthy Active Lifestyle Mobile App
  • Median Technologies Inks a Research Collaboration Agreement for Lung Cancer Screening Programs With Xingtai People’s Hospital, Xingtai City, China
  • Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A
  • Orthocell Commences Treatment of Its 1,000th Patient